Skip to main content

Considerations for Ensuring Safety and Efficacy of Vaccines and Therapeutic Proteins Manufactured by Using Platform Approaches Summary of a Workshop (2010) / Chapter Skim
Currently Skimming:

Appendix B AGENDA
Pages 17-18

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 17...
...  TMTI  Jonathan Coffman, Ph.D.; Wyeth BioPharma  Phil Gomez, Ph.D., Principal, PRTM  Mark A Schenerman, Ph.D.; Vice President, Analytical Biochemistry, MedImmune 12:45 Lunch 1:30 Process Of Using Platform Approach To Facilitate FDA Approval: Insight From Merck Yeast Platform Products David K
Read the entire page →
From page 18...
... Schenerman, Ph.D.; Vice President, Analytical Biochemistry, MedImmune 3:15 Discussion of Questions Prepared by Committee Peter Patriarca 4:00 Break 4:15 Continued Discussion of Questions Prepared by Committee 5:15 Summary's of Today's Themes Peter Patriarca 5:30 Adjourn 18
Read the entire page →

Key Terms

  • phil gomez
  • using platform
  • peter patriarca
  • analytical biochemistry
  • questions prepared

  • antibody platforms
  • global process
  • therapeutic proteins
  • business development
  • facilitate fda

  • antibody development
  • discovery deputy
  • continued discussion
  • tmti discovery
  • brian reinhardt

  • platform technologies
  • senior director
  • brian kelley
  • bioprocess development
  • process development

  • platform approach
  • dane zabriskie
  • amgen inc
  • pascal longchamp
  • vice president

  • jonathan coffman
  • wyeth biopharma
  • merck yeast
  • biopharmaceuticals dane
  • senior clinical


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.